NOVOMEDLINK™
  1. Activella®

    (estradiol/norethindrone acetate tablets)

  2. Vagifem®

    (estradiol vaginal tablets)

  3. GlucaGen® HypoKit®

    (glucagon [rDNA Origin] for injection)

  4. Levemir®

    (insulin detemir [rDNA origin] injection)

  5. Norditropin®

    (somatropin (rDNA origin) injection)

  6. NovoLog®

    (Insulin aspart [rDNA origin] injection)

  7. NovoLog® Mix 70/30

    (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])

  8. NovoSeven® RT

    Coagulation Factor VIIa (Recombinant) Room
    Temperature Stable

  9. NovoSeven®

    (Coagulation Factor VIIa [Recombinant])

For patients with type 2 diabetes,

The proven weight benefits of Levemir®102,103

Levemir® demonstrated significantly less weight gain* when compared with insulin glargine102,103

In a 52-week clinical study, patients with type 2 diabetes gained 26% less weight with Levemir® than with insulin glargine.103

Levemir® demonstrates less weight gain* than insulin glargine

A 52-week, multinational, open-label, parallel-group, treat-to-target trial using a noninferiority design. Subjects diagnosed with type 2 diabetes ≥12 months on any OAD therapy or on any insulin regimen with or without OAD therapy for >4 months were randomized 2:1 to the Levemir® and insulin glargine treatment arms, respectively. A total of 323 patients were randomized; 257 completed the study. In both treatment groups, insulin aspart was administered as a mealtime insulin.103

  • Less weight gain* was confirmed in 12 of 12 controlled clinical trials13
    • Patients with type 1 diabetes
    • Patients with type 2 diabetes
    • Patients previously treated with OAD therapy alone
eLearning Presentation


Observed weight change with Levemir®

Results from the German cohort of PREDICTIVE® (N=10,276), an ongoing, multicenter, observational study evaluating the safety and efficacy of Levemir® in patients with diabetes over 14.5 weeks. Subgroup analyses of patients with type 2 diabetes further evaluated the safety and efficacy of Levemir® when adding or switching from OAD therapy (n=1321), NPH insulin ± OAD therapy (n=251), or insulin glargine ± OAD therapy (n=260).11

PREDICTIVE = Predictable Results and Experience in Diabetes through Intensification and Control to Target: an International Variability Evaluation.

*Whether these observed differences represent true differences in the effects of Levemir®, NPH insulin, and insulin glargine is not known, since these trials were not blinded and the protocols (eg, diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.

A retrospective analysis showed weight benefits for overweight or obese patients with type 2 diabetes when starting Levemir®108

Levemir® weight change: retrospective analysis

Results from a 20-week, multicenter, randomized, open-label clinical trial comparing the efficacy and safety of Levemir® with NPH insulin administered once daily. OAD medication was administered to both treatment groups (N=331).108

  • In a retrospective analysis of a separate 26-week study, patients with a mean baseline BMI >30 kg/m2 experienced a beneficial weight change107

Results from PREDICTIVE® 303 (N=5604), a multicenter, parallel-group clinical study evaluating the efficacy and safety of Levemir® in patients with type 2 diabetes over 26 weeks. Subgroup analyses further evaluated the efficacy and safety of Levemir® patients' previous regimens: OAD therapy (n=1874), NPH insulin ± OAD therapy (n=279), or insulin glargine ± OAD therapy (n=1337). Patients either self-titrated their Levemir® dose to target FPG levels or had their dose adjusted by a physician according to standard of care.1,109

With Levemir®, your patients may experience less weight gain.102,103* Learn more about the benefits of Levemir®.

  1. Levemir® (insulin detemir [rDNA origin] injection) Indications and Usage

    Levemir® is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

    Levemir® Important Safety Information

    Levemir® is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

    Levemir® should not be diluted or mixed with any other insulin preparations.

    Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir®. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Levemir® is not to be used in insulin infusion pumps. Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

    Needles and Levemir® FlexPen® must not be shared.

    Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis.Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir® from other intermediate or long-acting insulin preparations. The dose of Levemir® may need to be adjusted in patients with renal or hepatic impairment.

    Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation. Less common but more serious are severe cases of generalized allergy, including anaphylactic reaction, which may be life threatening.

    *Whether these observed differences represent true differences in the effects of Levemir®, NPH insulin, and insulin glargine is not known, since these trials were not blinded and the protocols (eg, diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.

    Please see Prescribing InformationPrescribing Information.

  2. NovoLog® (insulin aspart [rDNA origin] injection) Indications and Usage

    NovoLog® is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

    NovoLog® Important Safety Information

    NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.

    NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. An injection of NovoLog® should be immediately followed by a meal within 5 to 10 minutes. Because of the short duration of action of NovoLog®, a longer-acting insulin also should be used in patients with type 1 diabetes and may be needed in patients with type 2 diabetes. When used in an external subcutaneous insulin infusion pump, NovoLog® should not be mixed with any other insulin or diluent. Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulins.

    Any change of insulin dose should be made cautiously and only under medical supervision. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity.

    Needles and NovoLog® FlexPen® must not be shared.

    NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes under the age of two.

    Severe, life-threatening generalized allergy, including anaphylactic reaction, may occur with any insulin product, including NovoLog®. Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given intravenously or in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment.

    Please see Prescribing InformationPrescribing Information.

  3. NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) Indications and Usage

    NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is indicated for the treatment of patients with diabetes mellitus for the control of hyperglycemia.

    NovoLog® Mix 70/30 Important Safety Information

    NovoLog® Mix 70/30 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® Mix 70/30 or one of its excipients. 

    Because NovoLog® Mix 70/30 has peak pharmacodynamic activity 1 hour after injection, it should be administered with meals.  Hypoglycemia is the most common adverse effect of insulin therapy, including NovoLog® Mix 70/30.  As with all insulins, the timing of hypoglycemia may differ among various insulin formulations.  Glucose monitoring is recommended for all patients with diabetes.  Any change of insulin should be made cautiously and only under medical supervision.  Changes in insulin strength, manufacturer, type, species, or method of manufacture may result in theneed for a change in dosage.  

    Because of differences in the action of NovoLog® Mix 70/30 and other insulins, care should be taken in patients in whom these conditions may be clinically relevant (e.g. patients who are fasting, have autonomicneuropathy, are using potassium-lowering drugs, or are taking drugs sensitive to serum potassium level).  Do not mix NovoLog® Mix 70/30 with any other insulin product. 

    Needles and NovoLog® Mix 70/30 FlexPen® must not be shared.

    Potential side effects associated with the use of all insulins include hypoglycemia, hypokalemia, lipodystrophy and allergic reactions. As with other insulin therapy, erythema, swelling and pruritis at the injection site have been observed with NovoLog® Mix 70/30.  Less common, but more serious are severe cases of generalized allergy, including anaphylactic reaction, which may be life threatening.  NovoLog® Mix 70/30 dose requirements may be reduced in the presence of renal impairment or impaired hepaticfunction. 

    Please see Prescribing InformationPrescribing Information.

FlexPen®, GlucaGen®, HypoKit®, Levemir®, NovoFine®, and NovoLog® are registered trademarks and NovoMedLink™ is a trademark of Novo Nordisk A/S. Norditropin® and NovoSeven® are registered trademarks of Novo Nordisk Health Care AG. Activella® and Vagifem® are registered trademarks of Novo Nordisk FemCare AG.